Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Metabolic conditions with increased risk included type 2 diabetes (RR 1.26, 95% CI 1.16 to 1.36) and vitamin D deficiency (RR 1.19, 95% CI 1.09 to 1.30).
Source: Incident high-risk conditions at mid and late-stage post-acute periods in outpatient COVID-19 cases. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
COVID-19 patients were further classified as hospitalized (inpatient) or non-hospitalized (outpatient) based on whether or not they had a hospital admission between 7 days before or 14 days after a positive PCR test.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
International electronic health record-derived post-acute sequelae profiles of COVID-19 patients
Study design awaiting verification · NPJ Digital Medicine · 2022
Original publication title
International electronic health record-derived post-acute sequelae profiles of COVID-19 patients
© The Author(s) 2022
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
The risk profiles of post-acute sequelae of COVID-19 (PASC) have not been well characterized in multi-national settings with appropriate controls. We leveraged electronic health record (EHR) data from 277 international hospitals representing 414,602 patients with COVID-19, 2.3 million control patients without COVID-19 in the inpatient and outpatient settings, and over 221 million diagnosis codes to systematically identify new-onset conditions enriched among patients with COVID-19 during the post-acute period. Compared to inpatient controls, inpatient COVID-19 cases were at significant risk for angina pectoris (RR 1.30, 95% CI 1.09 to 1.55), heart failure (RR 1.22, 95% CI 1.10 to 1.35), cognitive dysfunctions (RR 1.18, 95% CI 1.07 to 1.31), and fatigue (RR 1.18, 95% CI 1.07 to 1.30).
Relative to outpatient controls, outpatient COVID-19 cases were at risk for pulmonary embolism (RR 2.10, 95% CI 1.58 to 2.76), venous embolism (RR 1.34, 95% CI 1.17 to 1.54), atrial fibrillation (RR 1.30, 95% CI 1.13 to 1.50), type 2 diabetes (RR 1.26, 95% CI 1.16 to 1.36) and vitamin D deficiency (RR 1.19, 95% CI 1.09 to 1.30). Outpatient COVID-19 cases were also at risk for loss of smell and taste (RR 2.42, 95% CI 1.90 to 3.06), inflammatory neuropathy (RR 1.66, 95% CI 1.21 to 2.27), and cognitive dysfunction (RR 1.18, 95% CI 1.04 to 1.33).
The incidence of post-acute cardiovascular and pulmonary conditions decreased across time among inpatient cases while the incidence of cardiovascular, digestive, and metabolic conditions increased among outpatient cases. Our study, based on a federated international network, systematically identified robust conditions associated with PASC compared to control groups, underscoring the multifaceted cardiovascular and neurological phenotype profiles of PASC.
Authors’ abstract
The risk profiles of post-acute sequelae of COVID-19 (PASC) have not been well characterized in multi-national settings with appropriate controls. We leveraged electronic health record (EHR) data from 277 international hospitals representing 414,602 patients with COVID-19, 2.3 million control patients without COVID-19 in the inpatient and outpatient settings, and over 221 million diagnosis codes to systematically identify new-onset conditions enriched among patients with COVID-19 during the post-acute period. Compared to inpatient controls, inpatient COVID-19 cases were at significant risk for angina pectoris (RR 1.30, 95% CI 1.09 to 1.55), heart failure (RR 1.22, 95% CI 1.10 to 1.35), cognitive dysfunctions (RR 1.18, 95% CI 1.07 to 1.31), and fatigue (RR 1.18, 95% CI 1.07 to 1.30).
Relative to outpatient controls, outpatient COVID-19 cases were at risk for pulmonary embolism (RR 2.10, 95% CI 1.58 to 2.76), venous embolism (RR 1.34, 95% CI 1.17 to 1.54), atrial fibrillation (RR 1.30, 95% CI 1.13 to 1.50), type 2 diabetes (RR 1.26, 95% CI 1.16 to 1.36) and vitamin D deficiency (RR 1.19, 95% CI 1.09 to 1.30). Outpatient COVID-19 cases were also at risk for loss of smell and taste (RR 2.42, 95% CI 1.90 to 3.06), inflammatory neuropathy (RR 1.66, 95% CI 1.21 to 2.27), and cognitive dysfunction (RR 1.18, 95% CI 1.04 to 1.33).
The incidence of post-acute cardiovascular and pulmonary conditions decreased across time among inpatient cases while the incidence of cardiovascular, digestive, and metabolic conditions increased among outpatient cases. Our study, based on a federated international network, systematically identified robust conditions associated with PASC compared to control groups, underscoring the multifaceted cardiovascular and neurological phenotype profiles of PASC.
Publication and source details
Original title: International electronic health record-derived post-acute sequelae profiles of COVID-19 patients
Harrison G. Zhang; Arianna Dagliati; Zahra Shakeri Hossein Abad; Xin Xiong; Clara-Lea Bonzel; Zongqi Xia; Bryce W. Q. Tan; Paul Avillach; Gabriel A. Brat; Chuan Hong; Michele Morris; Shyam Visweswaran; Lav P. Patel; Alba Gutiérrez-Sacristán; David A. Hanauer; John H. Holmes; Malarkodi Jebathilagam Samayamuthu; Florence T. Bourgeois; Sehi L’Yi; Sarah E. Maidlow; Bertrand Moal; Shawn N. Murphy; Zachary H. Strasser; Antoine Neuraz; Kee Yuan Ngiam; Ne Hooi Will Loh; Gilbert S. Omenn; Andrea Prunotto; Lauren A. Dalvin; Jeffrey G. Klann; Petra Schubert; Fernando J. Sanz Vidorreta; Vincent Benoit; Guillaume Verdy; Ramakanth Kavuluru; Hossein Estiri; Yuan Luo; Alberto Malovini; Valentina Tibollo; Riccardo Bellazzi; Kelly Cho; Yuk-Lam Ho; Amelia L. M. Tan; Byorn W. L. Tan; Nils Gehlenborg; Sara Lozano-Zahonero; Vianney Jouhet; Luca Chiovato; Bruce J. Aronow; Emma M. S. Toh; Wei Gen Scott Wong; Sara Pizzimenti; Kavishwar B. Wagholikar; Mauro Bucalo; The Consortium for Clinical Characterization of COVID-19 by EHR (4CE); Tianxi Cai; Andrew M. South; Isaac S. Kohane; Griffin M. Weber
NPJ Digital Medicine · 2022
© The Author(s) 2022https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.https://doi.org/10.13039/100006108U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (NCATS)UL1TR002541UL1TR000005UL1TR001857UL1TR001857CTSA Award #UL1TR002366UL1TR002240UL1TR0022405UL1TR001857-05UL1TR001881UL1TR001998UL1TR001420Morris Michele Visweswaran Shyam Patel Lav P. Hanauer David A. Maidlow Sarah E. Murphy Shawn N. Vidorreta Fernando J. Sanz Kavuluru Ramakanth South Andrew M. Weber Griffin M. U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (NCATS)https://doi.org/10.13039/100000092U.S. Department of Health & Human Services | NIH | U.S. National Library of Medicine (NLM)R01LM013345R01LM013337T15 LM007092Luo Yuan Gehlenborg Nils Weber Griffin M. https://doi.org/10.13039/100000051U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (NHGRI)3U01HG008685-05S25R01HG009174-04Murphy Shawn N. Weber Griffin M. https://doi.org/10.13039/100000065U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)R01NS098023Xia Zongqi National Medical Research Council Research Training Fellowship (MOH-000195-00).U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (NCATS)U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (NCATS)U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (NCATS)U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (NCATS)U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (NCATS)U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (NCATS)U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (NHGRI)https://doi.org/10.13039/100000002U.S. Department of Health & Human Services | National Institutes of Health (NIH)P30ES017885U24CA210967Omenn Gilbert S. U.S. Department of Health & Human Services | National Institutes of Health (NIH)U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (NCATS)U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (NCATS)U.S. Department of Health & Human Services | NIH | U.S. National Library of Medicine (NLM)EU PROJECT H2020 PERISCOPE: 101016233VA MVP000 and CIPHERU.S. Department of Health & Human Services | NIH | U.S. National Library of Medicine (NLM)https://doi.org/10.13039/100000050U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)U24 HL148865R01 HL151643-01K23HL148394L40HL148910Aronow Bruce J. Wagholikar Kavishwar B. South Andrew M. U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (NCATS)Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T09:54:08.850206+00:00
DOI: 10.1038/s41746-022-00623-8 · PMC9242995